NASDAQ:AXSM Axsome Therapeutics Q3 2026 Earnings Report $177.08 -2.17 (-1.21%) Closing price 10/5/2026 04:00 PM EasternExtended Trading$177.09 +0.01 (+0.01%) As of 08:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Axsome Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.51Beat/MissN/AOne Year Ago EPSN/AAxsome Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$257.35 millionBeat/MissN/AYoY Revenue GrowthN/AAxsome Therapeutics Announcement DetailsQuarterQ3 2026Date11/2/2026TimeBefore Market OpensConference Call DateMonday, November 2, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Axsome Therapeutics Earnings HeadlinesWhy Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM)October 5 at 3:42 PM | finance.yahoo.comFinancial Review: Gyre Therapeutics (NASDAQ:GYRE) and Axsome Therapeutics (NASDAQ:AXSM)October 4 at 4:15 AM | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 6 at 1:00 AM | Behind the Markets (Ad)Head-To-Head Survey: Vireo Growth (OTCMKTS:VREOD) versus Axsome Therapeutics (NASDAQ:AXSM)October 3 at 5:15 AM | americanbankingnews.comWells Fargo Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)October 2, 2026 | theglobeandmail.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Now Rated "Moderate Buy" by Wall Street BrokeragesOctober 2, 2026 | americanbankingnews.comSee More Axsome Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Axsome Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Axsome Therapeutics and other key companies, straight to your email. Email Address About Axsome TherapeuticsAxsome Therapeutics (NASDAQ:AXSM) is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. The company uses differentiated product candidates and targeted mechanisms to address conditions with significant unmet medical needs, including depression, sleep disorders, migraine, and other neurological or psychiatric diseases. Axsome’s lead commercial product is Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride), an oral medicine approved in the United States for the treatment of major depressive disorder in adults. The company also commercializes Sunosi (solriamfetol), which is approved to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Axsome acquired the U.S. rights to Sunosi from Jazz Pharmaceuticals in 2022. The company maintains a pipeline of investigational CNS therapies, including candidates being evaluated for disorders such as Alzheimer’s disease agitation, migraine, narcolepsy-related cataplexy, and fibromyalgia. Axsome was founded in 2012 and is headquartered in New York. Its operations and commercial activities are primarily focused on the United States. The company is led by founder and Chief Executive Officer Herriot Tabuteau, M.D.View Axsome Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
